Uptake of moss‐derived human recombinant GAA in Gaa−/− mice
Hintze S, Dabrowska-Schlepp P, Berg B, et al. Uptake of moss-derived human recombinant GAA in Gaa−/−mice. JIMDReports. 2021;1–9.https://doi.org/10.1002/jmd2.12203.
Publications
Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease
Hintze S, Limmer S, Dabrowska-Schlepp P, Berg B, Krieghoff N, Busch A, Schaaf A, Meinke P, Schoser B. 2020. nt J Mol Sci. 2020 Apr 10;21(7):2642. doi: 10.3390/ijms21072642.
CLARIOstar® determines activity of a moss-produced human acid alphaglucosidase (GAA) in a fluorescence-based assay
Berg B, Fischer A, Haessler F, Dabrowska-Schlepp P, Maurer F, Tintelnot S. 2019. BMG LABTECH. 339: Ortenberg.
Single‐Use Processing as a Safe and Convenient Way to Develop and Manufacture Moss‐Derived Biopharmaceuticals
Niederkrueger H, Busch A, Dabrowska-Schlepp P, Krieghoff N, Schaaf A, Frischmuth T. 2019. In: Eibl R, Eibl D, editors. Single-Use Technology in Biopharmaceutical Manufacture. 2nd ed. Hoboken, NJ: Wiley. p. 311-318.
Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease
Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. 2019. Journal of Inherited Metabolic Disease. 42(3): Hoboken, NJ.
Real-time VCD monitoring of moss for therapeutic protein production
Koch J, Mueller M, Niederkrueger H. 2018. Hamilton. Bonaduz.
Pharmacokinetics, pharmacodynamics, and safety of moss agalactosidase A in patients with Fabry disease
Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. 2018. 123(2): Cambridge.
Treatment of experimental C3 Glomerulopathy by human complement factor H produced in glycosylation-optimized Physcomitrella patens
Haeffner K, Parsons J, Bohlender L, Hoernstein S, Niederkrueger H, Fode B, Busch A, Krieghoff N, Koch J, Schaaf A, Frischmuth T, Zipfel P, Pohl M, Reski R, Decker E, Michelfelder S. 2017. Molecular Immunology. 89: Oxford.